Watchlist Price Alert

Coherus BioSciences Inc. (CHRS)

NASDAQ: CHRS · Real-Time Price · USD

0.78

0.02 (2.40%)

At close: Jun 16, 2025, 3:59 PM

0.79

1.79%

After-hours: Jun 16, 2025, 07:30 PM EDT

2.40% (1D)

Bid	0.77
Market Cap	89.96M
Revenue (ttm)	197.5M
Net Income (ttm)	-130.94M
EPS (ttm)	0.42
PE Ratio (ttm)	1.85
Forward PE	-0.97
Analyst	Buy

Ask	0.81
Volume	961,067
Avg. Volume (20D)	1,685,988
Open	0.75
Previous Close	0.76
Day's Range	0.73 - 0.79
52-Week Range	0.66 - 2.43
Beta	0.88

About CHRS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CHRS

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CHRS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 month ago

-19.11%

Coherus BioSciences shares are trading lower. The ... Unlock content with Pro Subscription

2 months ago

+16.59%

Coherus BioSciences shares are trading higher after the company announced it completed UDENYCA franchise divestiture.

News

1 month ago · seekingalpha.com

Coherus BioSciences, Inc. (CHRS) Q1 2025 Earnings Call Transcript

Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q1 2025 Earnings Conference Call May 12, 2025 5:00 PM ET Company Participants Jodi Sievers - Head, Investor Relations Denny Lanfear - Chief Executive Officer T...

1 month ago · zacks.com

Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates

Coherus BioSciences (CHRS) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.32 per share a year ago.

2 months ago · seekingalpha.com

Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs

Coherus BioSciences is now heavily focused on developing its pipeline, particularly casdozokitug and CHS-114, after shedding its marketed biosimilar drugs. Casdozokitug shows promise in metastatic hep...